The prevalence of patients suffering from chronic spontaneous urticaria, in whom omalizumab cannot be stopped even after six years.

IF 3.3 Q2 ALLERGY
Frontiers in allergy Pub Date : 2024-10-02 eCollection Date: 2024-01-01 DOI:10.3389/falgy.2024.1464466
V Schichter-Konfino, R Mubariki, E Toubi, Z Vadasz
{"title":"The prevalence of patients suffering from chronic spontaneous urticaria, in whom omalizumab cannot be stopped even after six years.","authors":"V Schichter-Konfino, R Mubariki, E Toubi, Z Vadasz","doi":"10.3389/falgy.2024.1464466","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Omalizumab (OMA) was the first FDA-approved biological drug for severe chronic spontaneous urticaria (CSU), and until today is the only beneficial and truly safe one. The objectives were: To assess the prevalence of CSU patients in whom OMA cannot be stopped over time. We also asked if biomarkers (e.g., anti-TPO antibodies and total IgE) could assist in anticipating this issue.</p><p><strong>Methods: </strong>We used our prospective registry of 93 patients, which included CSU disease duration, the onset of OMA treatment, Urticaria Activity Score (UAS7) during follow-up, co-morbidities, serum IgE levels and the presence of anti-TPO antibodies. Finally, we assessed the response to OMA during a period of six years.</p><p><strong>Results: </strong>Out of the 93 treated CSU patients, OMA was stopped in ten patients after six months being defined as failures. In another ten patients, OMA was discontinued after 2-4 years of therapy, achieving a remission. Seventy-three patients are still treated between 2 and 6 years, having different degrees of response. Of these, in thirty-eight (52%) patients, we could not stop OMA even after six years due to CSU relapses. The prevalence of lower serum IgE levels and anti-TPO antibody positivity was significantly higher in CSU patients in whom OMA could not be stopped.</p><p><strong>Conclusion: </strong>This is the first study where OMA-treated CSU patients were followed up to six years. In half of them, long-term therapy of six years is still required.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"5 ","pages":"1464466"},"PeriodicalIF":3.3000,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480063/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/falgy.2024.1464466","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Omalizumab (OMA) was the first FDA-approved biological drug for severe chronic spontaneous urticaria (CSU), and until today is the only beneficial and truly safe one. The objectives were: To assess the prevalence of CSU patients in whom OMA cannot be stopped over time. We also asked if biomarkers (e.g., anti-TPO antibodies and total IgE) could assist in anticipating this issue.

Methods: We used our prospective registry of 93 patients, which included CSU disease duration, the onset of OMA treatment, Urticaria Activity Score (UAS7) during follow-up, co-morbidities, serum IgE levels and the presence of anti-TPO antibodies. Finally, we assessed the response to OMA during a period of six years.

Results: Out of the 93 treated CSU patients, OMA was stopped in ten patients after six months being defined as failures. In another ten patients, OMA was discontinued after 2-4 years of therapy, achieving a remission. Seventy-three patients are still treated between 2 and 6 years, having different degrees of response. Of these, in thirty-eight (52%) patients, we could not stop OMA even after six years due to CSU relapses. The prevalence of lower serum IgE levels and anti-TPO antibody positivity was significantly higher in CSU patients in whom OMA could not be stopped.

Conclusion: This is the first study where OMA-treated CSU patients were followed up to six years. In half of them, long-term therapy of six years is still required.

慢性自发性荨麻疹患者的发病率,这些患者在六年后仍无法停用奥马珠单抗。
背景:奥马珠单抗(Omalizumab,OMA)是美国食品及药物管理局(FDA)批准的第一种治疗严重慢性自发性荨麻疹(CSU)的生物药物,也是迄今为止唯一有效且真正安全的药物。我们的目标是评估长期无法停用 OMA 的 CSU 患者的患病率。我们还询问生物标志物(如抗TPO 抗体和总 IgE)是否有助于预测这一问题:我们对 93 名患者进行了前瞻性登记,其中包括 CSU 病程、开始接受 OMA 治疗的时间、随访期间的荨麻疹活动评分 (UAS7)、合并疾病、血清 IgE 水平以及是否存在抗TPO 抗体。最后,我们还评估了六年来对 OMA 的反应:在接受治疗的 93 名 CSU 患者中,有 10 名患者在 6 个月后停用了 OMA,被定义为治疗失败。另有 10 名患者在治疗 2-4 年后,病情得到缓解,停止了 OMA 的治疗。73名患者仍在接受2至6年的治疗,他们的反应程度各不相同。其中,有 38 名患者(52%)由于 CSU 复发,即使在 6 年后我们也无法停止 OMA 的治疗。在无法停用 OMA 的 CSU 患者中,血清 IgE 水平降低和抗TPO 抗体阳性的发生率明显更高:这是首次对接受过 OMA 治疗的 CSU 患者进行长达六年的随访研究。结论:这是第一项对接受过 OMA 治疗的 CSU 患者进行长达六年随访的研究,其中半数患者仍需接受六年的长期治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
0
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信